Colgate Announces Dividend Increase – Effective 2nd Quarter 2024

NEW YORK--(BUSINESS WIRE)-- The Board of Directors of Colgate-Palmolive Company (NYSE: CL) today increased the quarterly common stock cash dividend to $0.50 per share, up from $0.48 per share. The increase will be effective in the second quarter, 2024. The Board declared that the second quarter dividend is to be paid on May 15, 2024 to shareholders of record as of April 22, 2024. On an annualized basis, the new dividend rate is $2.00 versus $1.92 per share previously. The Company has paid uninterrupted dividends on its common stock since 1895.

* * *

Colgate-Palmolive Company is a caring, innovative growth company that is reimagining a healthier future for all people, their pets and our planet. Focused on Oral Care, Personal Care, Home Care and Pet Nutrition, we sell our products in more than 200 countries and territories under brands such as Colgate, Palmolive, elmex, hello, meridol, Sorriso, Tom’s of Maine, EltaMD, Filorga, Irish Spring, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Soupline and Suavitel, as well as Hill’s Science Diet and Hill’s Prescription Diet. We are recognized for our leadership and innovation in promoting sustainability and community wellbeing, including our achievements in decreasing plastic waste and promoting recyclability, saving water, conserving natural resources and improving children’s oral health through the Colgate Bright Smiles, Bright Futures program, which has reached approximately 1.7 billion children and their families since 1991. For more information about Colgate’s global business and how we are building a future to smile about, visit www.colgatepalmolive.com. CL-D

View source version on businesswire.com: https://www.businesswire.com/news/home/20240308075581/en/

Investor Relations: [email protected]
Communications: [email protected]

Source: Colgate-Palmolive Company

You May Also Be Interested In

• Primemas Shatters AI Memory Wall at FMS 2026 with CXL Full-Stack Products and Micron Collaboration on the Abaco Project
• Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
• Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Signs New FF Par Agreement with a Leading U.S. Robotics Distributor and Provides Details on FF EAI Robotics “Built in USA�